The Health and Social Care Act 2012 (Commencement No. 12) Order 2026, made on 15 July 2026 and published on legislation.gov.uk, appoints 1 October 2026 as the date when section 208 of the 2012 Act comes into force so far as it is not already in force. The instrument was signed by Stephen Kinnock, Minister of State at the Department of Health and Social Care, acting under section 306 of the Act. For legal and policy readers, the immediate point is narrow but clear. This Order does not rewrite the 2012 settlement; it brings an existing provision into legal effect on a specified date.
That procedural role is typical of a commencement order. Parliament passed the parent Act in 2012, but not every section had to start on the same day. The explanatory note says this is the twelfth order made under the Act, which places section 208 within a longer pattern of staged implementation. The note also lists earlier commencement orders made between 2012 and 2018. That record matters because it shows this is a finalising step in a long legislative timetable rather than a stand-alone reform package announced in 2026.
The provision now being activated is section 208. According to the explanatory note on legislation.gov.uk, that section amends the National Health Service Act 2006 so that the NHS Commissioning Board, now NHS England, may establish lists of Local Pharmaceutical Service performers and of those who assist pharmaceutical contractors in providing pharmaceutical services. In practical terms, the section is about formal records within the NHS pharmaceutical services framework. The emphasis is on the individuals performing or supporting service delivery, not only on the contractor organisation holding the service arrangement.
For NHS England, the change matters because it gives live statutory effect to a power connected to oversight and administration in this part of pharmaceutical provision. Where an Act authorises the creation of lists, it gives the national body a defined legal route to record the people involved in service delivery. The explanatory note is also careful to update the institutional language. Although the 2012 Act referred to the NHS Commissioning Board, the note states that the body is now NHS England, which is the organisation affected in practice from 1 October 2026.
For pharmaceutical contractors, performers and those assisting in the delivery of services, the practical consequence is the commencement date itself. From 1 October 2026, the remaining uncommenced parts of section 208 will be active, and any arrangements dependent on that section will rest on an operative statutory basis. What this Order does not do is just as important. It does not set out application rules, professional standards, enforcement steps or local operating guidance. Those matters, where relevant, sit elsewhere in the legislative or administrative framework.
On costs and wider effects, the Department of Health and Social Care states that no separate full impact assessment has been produced for this instrument because the Order itself has no impact on the private sector or civil society organisations. Instead, the government points to the fuller impact assessment prepared for the Health and Social Care Bill 2011 and for the Act more broadly. That distinction is significant for policy reporting. The commencement order is treated as a procedural measure, while the substantive policy effects were assessed at the point the wider legislation was developed.
The result is a short instrument with a focused legal purpose. Its policy value lies less in new ministerial announcement and more in legal activation: section 208 will be in force from 1 October 2026 wherever it was not already commenced. For NHS England and those involved in Local Pharmaceutical Service delivery, that date is the operational marker. It is the point at which the statutory basis described in section 208 is available for the establishment of the relevant performer and assistant lists.